Results 11 to 20 of about 9,605 (202)

Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar

Therapeutic Advances in Gastroenterology, 2023
Background: Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this sign
Rosanne W. Meijboom, Helga Gardarsdottir, Matthijs L. Becker, Kris L. L. Movig, Johan Kuijvenhoven, Toine C. G. Egberts, Thijs J. Giezen   +6 more
doaj   +1 more source

Biosimilars [PDF]

Therapeutische Umschau, 2011
Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire   +6 more sources

Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation [PDF]

Терапевтический архив, 2019
Real - life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of inflammatory bowel diseases (IBD) is lacking. Aim.
O V Knyazev, T V Shkurko, A V Kagramanova, A A Lishchinskaya, M Yu Zvyaglova, I A Korneeva, A F Babayan, A I Parfenov   +7 more
doaj   +1 more source

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

Pharmaceutics, 2020
Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior
Ioana Gherghescu, M. Begoña Delgado-Charro   +1 more
doaj   +1 more source

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

Frontiers in Oncology, 2023
BackgroundBevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation.
Zhiting Zhao, Luqing Zhao, Guohao Xia, Jianwei Lu, Jianwei Lu, Bo Shen, Guoren Zhou, Fenglei Wu, Xiao Hu, Jifeng Feng, Shaorong Yu, Shaorong Yu   +11 more
doaj   +1 more source

Etanercept biosimilars [PDF]

Rheumatology International, 2014
Etanercept was the first tumour necrosis factor alpha antagonist approved in the USA for the treatment of rheumatoid arthritis, in 1998, and then for other diseases. With the etanercept patent set to expire in the EU in 2015, a number of etanercept copies have reached the production phase and are undergoing clinical trials, with the promise of being ...
Azevedo, Valderilio F., Galli, Nathalia, Kleinfelder, Alais, D’Ippolito, Julia, Urbano, Paulo C. M.   +4 more
openaire   +2 more sources

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Терапевтический архив, 2021
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov   +7 more
doaj   +1 more source

What do oncologists need to know about biosimilar products?

Chinese Journal of Cancer, 2016
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.
Linda K. S. Leung, Kevin Mok, Calvin Liu, Stephen L. Chan   +3 more
doaj   +1 more source

Key drivers for market penetration of biosimilars in Europe

Journal of Market Access & Health Policy, 2017
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available ...
Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi   +5 more
doaj   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

ACR Open Rheumatology, 2020
Objective It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Nick Bansback, Jeffrey R. Curtis, Jie Huang, Zeling He, Michael Evans, Tracy Johansson, Kaleb Michaud, Gabriela Schmajuk, Katherine P. Liao   +8 more
doaj   +1 more source